Risk factors to consider for extended anticoagulant therapy: a review of guidelines
CADTH
Record ID 32014000218
English
Authors' recommendations:
There was one evidence-based guideline identified that evaluated risks and benefits of extended duration anticoagulation. The guidelines state that decision to extend anticoagulation therapy beyond the standard three month treatment should consider the patients risk of recurrent VTE, major bleeding and their preferences. The primary individual risk factors for VTE recurrence that may warrant extended anticoagulation include the presence of active cancer, experiencing a second unprovoked VTE, or a first episode of unprovoked proximal deep vein thrombosis (DVT) or pulmonary embolism (PE). In patients with a high bleeding risk, the benefit of extended therapy may be outweighed by the increased risk of major bleeding.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/pdf/htis/feb-2013/RC0428%20Extended%20duration%20anticoagulation%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Risk Assessment
- Venous Thromboembolism
- Risk Factors
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.